BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo

Reuters
Jan 08
BRIEF-Tvardi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo

Jan 8 (Reuters) - Tvardi Therapeutics Inc TVRD.O:

  • TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DECREASE VERSUS 2.4% PLACEBO

  • TVARDI THERAPEUTICS INC - TOPLINE HEALTHY VOLUNTEER DATA FROM PHASE 1 STUDY OF NEXT-GENERATION STAT3 INHIBITOR, TTI-109, ON TRACK FOR H1 2026

Source text: ID:nGNX2MMRKZ

Further company coverage: TVRD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10